Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGCG | Q16739 | 7/20 | 0.46 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 7/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 2/20 | 0.37 |
| ▸ | AXL | P30530 | 2/20 | 0.37 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.37 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907661 | 0.90 | UGCG (0.47) | UGCGHCRTR1HCRTR2DHODHSCN9A | |
| SCHEMBL29601829 | 0.89 | UGCG (0.59) | UGCGHCRTR1HCRTR2METAXL | |
| SCHEMBL29907458 | 0.87 | UGCG (0.47) | UGCGHCRTR1HCRTR2SCN9AMET | |
| SCHEMBL24464264 | 0.85 | UGCG (0.46) | UGCGHCRTR1HCRTR2SCN9A | |
| SCHEMBL29907559 | 0.85 | UGCG (0.46) | UGCGHCRTR1HCRTR2SCN9A | |
| SCHEMBL29907379 | 0.85 | UGCG (0.46) | UGCGHCRTR1HCRTR2SCN9A | |
| SCHEMBL29907363 | 0.85 | SCN9A (0.46) | UGCGDHODHSCN9A | |
| SCHEMBL29907665 | 0.84 | UGCG (0.47) | UGCGHCRTR1HCRTR2METAXL | |
| SCHEMBL29907424 | 0.84 | UGCG (0.51) | UGCGSCN9AMETAXLTYRO3 | |
| SCHEMBL29907631 | 0.83 | UGCG (0.44) | UGCGHCRTR1HCRTR2DHODHSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-09-15 | — | — | US | disclosed |
| EP-4005637-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2022-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289679-A1 | HETEROCYCLIC COMPOUND | GBA1, GBA2, GALC | UGCG 10/4885HCRTR1 1895/4885HCRTR2 724/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.